

### **REMARKS**

The specification has been amended to update the priority claim, to incorporate the sequence identifiers pursuant to 37 C.F.R. § 1.821(d) and the Sequence Listing pursuant to § 1.821(c), and to correct minor typographical errors.

Specifically, SEQ ID NO:89 describes the amino acid sequence of DP-107. Through inadvertent error, the 20<sup>th</sup> amino acid residue of DP-107 incorrectly read “Q” instead of “G” on pages 30, 32 and 33. The correct amino acid sequence of DP-107 is indicated in Figure 13, rows 5 and 8; Figure 14, rows 6 and 9; Figure 16, rows 3 and 4; Figure 17, rows 4, 7, 10 and 13; Figure 18, rows 4 and 5; and in co-pending U.S. Patent Application No. 08/374,666, which was incorporated by reference in the specification as originally filed on page 36, lines 17-21. Accordingly, the amino acid sequence of DP-107 has been amended on page 30, line 28; in Table II on page 32, line 27; and in Table IIA on page 33, line 27. Similarly, the amino acid sequences of DP-107 carboxy truncations in Table II on page 32 and the amino acid sequences of DP-107 amino truncations in Table IIA on page 33 have been amended. No new matter has been introduced by the above-made amendments.

**CONCLUSION**

Applicants respectfully request that the present amendment and remarks be entered and made of record in the instant application.

No fee is believed to be due in connection with this submission. However, should the Patent Office determine otherwise, please charge any required fee to Pennie and Edmonds LLP Deposit Account Number 16-1150.

Respectfully submitted,

Date: December 17, 2003

By: Stephen K. Sullivan, Reg. No. 43,171  
Laura A. Coruzzi 30,742  
Laura A. Coruzzi (Reg. No.)

**PENNIE & EDMONDS** LLP  
1155 Avenue of the Americas  
New York, New York 10036-2711  
(212) 790-9090